← boardnext 2027-10
VERU
Veru Inc.distress 6/10 · elevated risk$2.27+0%today-63% from 52w high
Metabolic / Obesity 1
Lead: Obesity & Overweight · target GLP-1 · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$28M
Runway
0.9 yrs
Shares 1y
+10%
Price & events
-15.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
-3.6%
1W
-25.5%
1M
-1.9%
3M
-19.1%
6M
-60.9%
1Y
-76.9%
2Y
-96.7%
5Y
-97.2%
All
Overview
- Market Cap
- $36.35M
- Volume
- 22.04K
- 52 Week Range
- $2.09 – $6.10
- Total Shares
- 16.05M
- Float Shares
- 13.48M
- Short %
- 4.72%
- % Held by Insiders
- 9.78%
- % Held by Institutions
- 24.58%
- RVOL
- 0.06x
- Beta
- -1.18
Pipeline stages · 2 programs
Enobosarm, Semaglutide (Wegovy) weekly injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Enobosarm, SemaglutideGLP-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-10 Estimated 50% readout ~2027-11-15 | Phase 2 | Enobosarm, Semaglutide (Wegovy) weekly injection | Obesity & Overweight, Mobility Disability, HOMA-IR | — | recruiting |
| 2025-04-11 | Phase 2 | Enobosarm, Semaglutide | Muscle Loss, Obesity | 168 | completed |
Catalyst news & presentations · 2
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-02partnershipenobosarm · Clinical supply agreement with Novo Nordisk to supply Wegovy for Phase 2b PLATEAU study; Veru retains full rights to enobosarm, grants right of first negotiation for future combination development.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-04Canaccord GenuityBuy
- 2026-05-15OppenheimerOutperform
- 2025-12-18Canaccord GenuityBuy
- 2025-08-13Raymond JamesOutperform
- 2025-01-02HC Wainwright & Co.Buy
- 2024-12-20HC Wainwright & Co.Buy
Competitors — GLP-1
Recent news
- 2026-07-16Veru Inc (VERU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-07-14Veru Inc. (VERU) Slips 7% as Selling Pressure Intensifies Near Key Support - Imbalance Zone - dars.gov.et
- 2026-07-07Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day - GlobeNewswire
- 2026-07-07Veru to present obesity drug research at 2026 s... - Pluang
- 2026-07-07Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day - Yahoo Finance
- 2026-07-05Veru Inc. Shares Decline Amidst Market Pressure; Key Support Levels in Focus - Hull Moving Average - dars.gov.et
- 2026-07-04Price to sales forward of Veru Inc. – NASDAQ:VERU - TradingView
- 2026-07-02Veru Establishes At-the-Market Equity Offering Program - TipRanks
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.